Overall, our findings unveil a previously unreported viral mimicry-related mechanism and could facilitate future clinical development of predictive and/or response biomarkers in the context of HDAC3 inhibition and lymphoma treatment. This evidence concerns the gene HDAC3 and lymphoma.